Medtronic PLC $MDT Stock Position Raised by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC lifted its position in Medtronic PLC (NYSE:MDT) by 48.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,500 shares of the medical technology company’s stock after buying an additional 14,104 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Medtronic were worth $4,095,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter valued at $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic during the third quarter worth $33,000. Tripletail Wealth Management LLC bought a new stake in Medtronic during the third quarter worth about $34,000. Finally, GFG Capital LLC acquired a new position in Medtronic during the 2nd quarter valued at about $36,000. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on MDT. JPMorgan Chase & Co. increased their target price on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Royal Bank Of Canada increased their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Wells Fargo & Company boosted their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Finally, Citigroup boosted their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Trading Down 2.2%

NYSE:MDT opened at $96.82 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The company’s 50-day simple moving average is $99.08 and its 200 day simple moving average is $94.99. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The firm has a market capitalization of $124.12 billion, a P/E ratio of 26.10, a PEG ratio of 2.55 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).